Tue. May 26th, 2026
Spread the love

The United Bank for Africa Plc (UBA) has announced its audited results for the full-year ended December 2019, recording impressive growth across top and bottom lines. According to the 2019 financials filed at the Nigerian Stock Exchange (NSE) last Friday, the bank’s gross earnings grew by 13.3% to N559.8 billion, compared to N494 billion recorded in the corresponding period of 2018. The bank’s total assets also grew by 15.1% to an unprecedented N5.6 trillion for the year under review. In its tradition of rewarding shareholders, the bank proposed a final dividend of 80 kobo for every ordinary share of 50 kobo for the financial year that ended December 31, 2019.

This was the first time the bank’s gross earnings and assets would respectively cross the N500 billion and N5 trillion marks. Notwithstanding the challenging business environment in Nigeria, the bank’s profit before tax was impressive at N111.3 billion, compared to the N106.8 billion recorded at the end of 2018.
Furthermore, its profit after tax rose by 13.3% to N89.1 billion, compared to the N78.6 billion recorded in 2018. On the cost side, UBA’s operating expenses grew 10.1% to N217.2 billion, as against the N197.3 billion in 2018, well below average inflation rate within the period, a reflection of cost efficiency gains.

These results depicted the bank’s deepening of its Pan-African business strategy, given the growth in the contribution of its 19 African subsidiaries to the Group’s net earnings and total assets. Ex-Nigeria operations’ contributed 46% to the Group’s profit before tax (PBT) in the year under review. In addition, UBA has been deploying innovative lifestyle products to expand its market share across sub-Saharan Africa, leveraging its presence in the United Kingdom, United States of America and France, to build a true Africa’s global bank, facilitating trade and capital flows between Africa and the rest of the world.

The final dividend of 80 kobo for every ordinary share of 50 kobo, which is subject to the affirmation of the shareholders at its Annual General Meeting, will bring the total dividend for the year to N1, as the bank had paid an interim dividend of 20 kobo earlier in the year.

The results showed that UBA recorded a remarkable 20.2% growth (to N2.1 trillion) in loans to customers, whilst customer deposits increased by 14.4% to N3.8 trillion, compared to N3.3 trillion recorded in the corresponding period of 2018. This reflected increased customer confidence, enhanced customer experience, early wins from the ongoing business transformation program and the deepening of its retail banking franchise.

Commenting on the result, the Group Managing Director/CEO, Kennedy Uzoka, noted that 2019 was important for UBA Group as it gained further market share in most of its countries of operation. “The year 2019 was a very remarkable one for UBA given the adverse market developments. Nonetheless, we achieved sizable growth in balance sheet and earnings, even as we reposition the bank for the future.
“Gross earnings crossed the N500 billion threshold to N559 billion, whilst total assets also crossed the N5 trillion mark for the first time to N5.6 trillion. Our strategy remains centred around unparalleled service to our esteemed customers.

“Accordingly, we are making significant investments in a technology-driven transformation journey. We have recorded early gains as shown in the 39 per cent growth in electronic banking income to N38.8 billion in 2019, from N27.9 billion in 2018. Our businesses are gaining commendable share in their markets across regions in Africa, as we deepen the scale and scope of our operations.”

Uzoka said he was excited about the synergy the UBA Group had built and the progress it had made in its transformation drive. “We have positioned the bank as a truly pan-African banking franchise, leveraging our operations in France, the UK and the USA, to deepen intra-African trade and facilitate capital flows between Africa and the rest of the world. In 2020, we will pursue aggressive deepening of market share in all our subsidiaries, leveraging technology, rich human resources and our customer-first strategy to win in all the markets we operate, notwithstanding the challenges of our operating environment,” he added.

Also speaking on the performance, the Group CFO, Ugo Nwaghodoh, said the bank was well-positioned to sustain impressive performance across key financial indices, adding that already, some of its previous investment in digital and technological transformation are already paying off significantly.

“We navigated the fragile yield environment in our largest market to deliver an eight per cent growth in net interest income to N221.9 billion. This was bolstered by a 7.8 per cent and 13.9 per cent growth in interest income from corporate loans and investment securities respectively as well as a four per cent cost of funds driven by our stable retail deposits.

“Resulting from cost efficiency gains within the year, cost-to-income ratio moderated to 62.7 per cent (64% in 2018), whilst profit for the year grew 13.3 per cent, to N89.1billion, translating to 16.2 per cent return on average equity (RoAE),” Nwaghodoh said.

United Bank for Africa Plc is a leading pan-African financial institution, offering diverse banking and payments services to more than eighteen (18) million customers, across 1,000 business offices and customer touch points in 20 African countries.

With presence in New York, London and Paris, UBA is connecting people and businesses across Africa through retail, commercial and corporate banking, innovative cross-border payments and remittances, trade finance and ancillary banking services.

By admin

You missed

From Tramadol to Canadian to Exol-5 The New Drug Destroying Nigerian Youths An Investigative Article .From Tramadol to Canadian to Exol-5: The New Drug Destroying Nigerian Youths An Investigative Report on the Shifting Landscape of Substance Abuse in Nigeria Nigeria faces a severe and evolving drug crisis, particularly among its youth. What began with the widespread abuse of Tramadol has progressed through mixtures like “Canadian” to newer pharmaceutical diversions such as Exol-5. This shift reflects deeper issues: easy access to prescription drugs, weak regulation, socioeconomic pressures, and aggressive street-level marketing. NDLEA operations and health studies reveal a public health emergency that threatens an entire generation. Phase 1: The Tramadol Epidemic (2010s–Early 2020s) Tramadol, a synthetic opioid prescribed for moderate to severe pain, became Nigeria’s most notorious street drug. Cheap, potent, and widely smuggled (often from India and other Asian countries), it offered users energy, euphoria, and pain relief — appealing to commercial drivers, laborers, students, and young men seeking confidence or stamina. Scale of the Problem: Millions of tablets seized annually by NDLEA. High prevalence among young males aged 15–35. Linked to increased crime, sexual violence, organ damage (kidney failure, seizures), and mental health breakdowns. Contributed to broader opioid misuse alongside codeine cough syrups. Government responses included tighter import controls and public awareness campaigns, but these only displaced demand to other substances rather than eliminating it. Phase 2: The Rise of “Canadian” (Mid-2020s) “Canadian” or “Canadian Loud” emerged as a popular code for high-grade cannabis (often indica-dominant strains) or cannabis mixed with other synthetics. It gained traction as users sought alternatives or combinations to Tramadol’s effects. This phase marked a move toward imported or locally cultivated premium weed, sometimes laced with stronger chemicals. Youths in urban centers like Lagos, Kano, Jos, and Onitsha embraced it for its perceived “cleaner” high compared to opioids. However, it fueled polydrug use — combining cannabis with opioids, sedatives, or alcohol — amplifying health risks. Phase 3: Exol-5 – The Current Threat (2024–2026) Exol-5 (Benzhexol Hydrochloride / Trihexyphenidyl 5mg), originally a prescription medication for Parkinson’s disease and drug-induced movement disorders, has become the latest pharmaceutical being heavily abused. Why Exol-5? Euphoric Effects: Users report intense euphoria, hallucinations, and a sense of detachment — making it attractive as a cheap “upper” or escape. Accessibility: Sold over-the-counter or on the black market despite being a controlled prescription drug. NDLEA has seized millions of pills in single operations (e.g., 3.1 million pills in Kano in late 2024, and over 5.6 million combined with Tramadol in other busts). Street Names: Exol, Artane, Benzhexol, “Farin Mallam” (in Northern Nigeria). Demographics: Prevalent among youths, laborers, and even psychiatric patients who divert prescriptions. Studies show abuse rates as high as 25% among certain outpatient groups. Health Consequences: Anticholinergic toxicity: Confusion, dry mouth, blurred vision, urinary retention, constipation, and in high doses — delirium, psychosis, seizures, and heart issues. Long-term: Cognitive impairment, addiction, exacerbated mental health disorders. Often mixed with Tramadol, codeine, or cannabis, creating dangerous synergies. In cities like Jos, Exol-5 sits alongside diazepam, Rohypnol, and Tramadol on street markets, easily available to teenagers and young adults. Why This Evolution Continues Supply-Side Failures: Porous borders, corrupt officials, and overproduction of pharmaceuticals enable diversion. Demand Drivers: Unemployment, poverty, peer pressure, trauma, and the pursuit of performance enhancement (e.g., for “hustle” culture). Weak Regulation: Many pharmacies sell restricted drugs without prescriptions. Online and street vendors fill gaps. Displacement Effect: Cracking down on one substance (Tramadol/codeine) pushes users and dealers toward the next available option. NDLEA reports ongoing large seizures, but the problem persists due to high profitability and low risk for mid-level distributors. Broader Impacts on Nigerian Youths Education: Increased dropout rates and poor academic performance. Mental Health: Rising cases of psychosis and depression. Economy: Lost productivity among the working-age population. Crime and Violence: Drug-fueled robberies, cultism, and family breakdowns. Public Health System Strain: Overburdened hospitals treating overdoses and chronic complications. Young people aged 15–39 remain the hardest hit, with national surveys showing drug use prevalence significantly above global averages. What Must Be Done Stronger Enforcement: Consistent prosecution of corrupt enablers and large-scale traffickers. Regulation: Crackdown on rogue pharmacies and better tracking of prescription drugs. Prevention & Rehabilitation: School programs, community outreach, and expanded treatment centers (currently woefully inadequate). Economic Alternatives: Address root causes like youth unemployment. Public Awareness: Honest campaigns highlighting real dangers of “Exol-5” and similar drugs. Conclusion From Tramadol’s opioid grip to “Canadian” cannabis culture and now Exol-5’s anticholinergic highs, Nigeria’s drug crisis is mutating faster than responses can contain it. Exol-5 represents the dangerous new frontier — a legitimate medicine turned youth destroyer due to misuse and greed. Without urgent, multi-layered intervention — combining supply disruption, demand reduction, and socioeconomic support — an entire generation risks being lost to addiction. The time for half-measures is over. Nigeria’s future depends on winning this fight.